Trial Profile
A Phase II Neoadjuvant Study of RAD001 (Everolimus) in Combination With Paclitaxel and Trastuzumab For Operable HER2 Positive Breast Cancer
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase II
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Everolimus (Primary) ; Paclitaxel (Primary) ; Trastuzumab (Primary)
- Indications Advanced breast cancer; Early breast cancer; HER2 positive breast cancer
- Focus Therapeutic Use
- 31 Oct 2011 Status changed from active, no longer recruiting to recruiting as reported by ClinicalTrials.gov.
- 02 Mar 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record
- 23 Jul 2010 New trial record